California, USA (CU)_ BioBlocks has been purchased by Genesis Biotechnology Group® (GBG) and its Contract Research Organization (CRO) subsidiary, Genesis Drug Discovery & DevelopmentTM (GD3). BioBlocks, based in San Diego since 2002, delivers medicinal chemistry drug discovery services and solutions to customers all over the world, from initial lead discovery phase to identification of development candidates.
This addition to the portfolio of chemistry services will allow GD3 member companies to enlarge and multiply their full-service drug research and discovery capabilities, thereby enhancing…
